Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Laminin (925-933): Practical Guide for Cell Adhesion & Migra

    2026-05-22

    Laminin (925-933): Technical Guidance for Cell Adhesion and Migration Research

    What This Product Solves

    Laminin (925-933) is a synthetic peptide representing residues 925-933 of the laminin B1 chain (sequence: Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg). As a defined fragment of an extracellular matrix glycoprotein, it is designed to specifically engage the laminin receptor, making it a valuable tool for researchers investigating cell adhesion, chemotaxis, and migration processes. Laminin B1 chain peptide application is especially relevant in protocols where full-length laminin's complexity or variability presents a challenge. By providing a standardized, reproducible modulator of cell-matrix interactions, this peptide enables quantitative and comparative studies in cancer metastasis inhibition, neurobiology, and basement membrane protein research.

    This product is particularly suited for cell adhesion peptide-based assays, including the stimulation of HT-1080 and CHO cell attachment and chemotaxis assays in B16F10 murine melanoma cells. It also functions as a competitive inhibitor for laminin-driven cell migration, supporting studies that require dissection of specific receptor-ligand interactions. For detailed assay planning and advanced protocol strategies, see related articles such as Laminin (925-933): Precision Cell Adhesion Peptide for ECM Research and Laminin (925-933): Defined Peptide Tool for Cell Migration Assays.

    Protocol Parameters

    • Cell adhesion assay | 100–300 µg/mL | Suitable for HT-1080 and CHO cell attachment studies | This concentration range is supported by product data demonstrating effective stimulation of cell attachment | Product dossier
    • Chemotaxis assay | 100–300 µg/mL | Applicable for B16F10 murine melanoma cell migration experiments | This range elicits approximately 30% of the maximal response compared to full-length laminin | Product dossier
    • Solubility for stock solution | ≥15.53 mg/mL in water, ≥17.77 mg/mL in ethanol, ≥48.35 mg/mL in DMSO | Stock preparation for most in vitro workflows | Enables flexible solvent choice for experimental compatibility; recommended to aliquot and store at -20°C | Product dossier
    • Solution stability | Short-term use recommended | All cell-based and in vitro assays | To maintain peptide integrity and reproducibility, prepare fresh solutions or use aliquoted stocks | Product dossier
    • Competitive inhibition of chemotaxis | 100–300 µg/mL | For studies requiring modulation of laminin-driven migration | Demonstrated ability to inhibit full-length laminin-induced responses at these concentrations | Product dossier

    Workflow Setup and QC Checklist

    • Confirm peptide identity and purity on receipt (mass spectrometry and/or HPLC, if available), referencing the batch documentation provided by APExBIO.
    • Dissolve Laminin (925-933) in the chosen solvent (water, ethanol, or DMSO) at concentrations compatible with downstream applications, following solubility guidelines from the product page.
    • Filter-sterilize stock solutions if required for cell culture use, and aliquot to minimize freeze-thaw cycles.
    • Store lyophilized or solution stocks at -20°C. Avoid repeated freeze-thaw to preserve peptide activity.
    • Incorporate appropriate negative and positive controls in each assay to benchmark cell adhesion and chemotaxis responses.
    • Document batch number, solubilization protocol, and storage conditions in laboratory records for reproducibility.

    Common Failure Modes and Fixes

    • Low or inconsistent cell attachment/migration response: Verify peptide concentration and solvent compatibility; ensure even coating or mixing in assay wells; prepare fresh peptide solutions to avoid degradation.
    • Peptide precipitation in solution: Confirm the chosen solvent supports the required working concentration; gently warm and vortex if needed; if precipitation persists, consider diluting stock into the assay buffer immediately prior to use.
    • Loss of peptide activity after storage: Aliquot stocks to single-use volumes and store at -20°C; avoid repeated freeze-thaw cycles.
    • Unexpected cell toxicity: Assess solvent carryover and ensure final DMSO or ethanol concentrations are non-toxic to the cell type used; include solvent-only controls in the assay.
    • Batch-to-batch variation in results: Record all lot numbers and preparation steps; cross-check with previous batches and, if possible, standardize controls across experiments.

    Scope and Limitations

    This laminin B1 chain peptide is designed for in vitro research on cell adhesion, migration, and chemotaxis, with demonstrated effectiveness in select cell lines and assay formats as outlined above. Its defined sequence and receptor specificity make it a strong choice for quantitative extracellular matrix studies and metastasis inhibition peptide workflows. However, Laminin (925-933) should not be used for diagnostic or therapeutic applications, and its performance may vary outside the defined concentration and cell line parameters. Researchers should validate assay-specific conditions and be aware that this peptide represents only one functional domain of the full laminin molecule, potentially limiting its utility in contexts where entire protein interactions are required.

    Conclusion

    Laminin (925-933) offers a precise, reproducible tool for dissecting cell adhesion and migration mechanisms in the context of basement membrane research. Its solubility and batch consistency from suppliers like APExBIO facilitate integration into standard and advanced cell-based assays. For protocols requiring defined modulation of laminin receptor pathways, this peptide provides actionable advantages over more complex or variable ECM components. Researchers are encouraged to reference both the APExBIO product page and established protocol summaries for optimal experimental planning.